JAMES P. STAPLETON - Corporate Board Profile

General Enterprise Ventures, Inc.

Filing Date	Source Excerpt
2006-04-17	James P. Stapleton is currently the Chief Financial Officer of BioNovo ... Currently, Mr. Stapleton serves on GEM's Board of Directors. ... The audit committee currently consists of one director, James Stapleton, who is "independent" ... The audit committee held two (2) meetings during the year ended December 31, 2005. ... Our directors did not receive any cash compensation for their services as directors during the year ended December 31, 2005. ... The audit committee also selects an accounting firm to be engaged as the Company's independent public accountants and provides oversight of legal, ethical and corporate governance matters.
2006-05-10	James P. Stapleton is currently the Chief Financial Officer of BioNovo ... Currently, Mr. Stapleton serves on GEM's Board of Directors. ... Our board of directors has determined that James P. Stapleton, an "independent" director ... The audit committee currently consists of one director, James Stapleton, who is "independent" ... The audit committee held two (2) meetings during the year ended December 31, 2005. ... Our directors did not receive any cash compensation for their services as directors during the year ended December 31, 2005.
2007-06-11	James P. Stapleton is currently the Chief Financial Officer of BioNovo (OTC BB BNVI), a pharmaceutical company. Currently, Mr. Stapleton serves on GEM’s Board of Directors. He also served as GEM’s CFO from Nov. 2003 through April 2004. Our audit committee currently consists of one director, James Stapleton, who is “independent” as independence for audit committee members is defined by the SEC Rules. Mr. Stapleton has been determined by the board of directors to meet the qualifications of an “audit committee financial expert” in accordance with SEC rules.
2008-04-25	James P. Stapleton is currently a consultant and advisor to small publicly traded companies. From May 2004 through July 2007 Mr. Stapleton was the Chief Financial Officer of Bionovo (NASDAQ BNVI) Mr. Stapleton served as GEM’s Chief Financial Officer from November 2003 through April 2004, and is no longer employed by GEM or the Company. He serves on GEM’s Board of Directors. From 1996 through 2002 Mr. Stapleton was employed in a variety of positions for Auxilio, Inc. (OTC BB AUXO), Prosoft Training (NASDAQ POSO), including Corporate Secretary, Vice President Investor relations, Chief Financial Officer, and other positions. Mr. Stapleton was Chief Financial Officer of BioTek Solutions, Inc. from 1995 through February 1996. The audit committee currently consists of one director, James Stapleton, who is “independent” as that term is defined in the rules of the NASDAQ stock market pertaining to the NASDAQ Capital Market. Mr. Stapleton has been determined by the board of directors to meet the qualifications of an “audit committee financial expert” in accordance with SEC rules, including that the person meets the relevant definition of an “independent director.”
2009-05-08	Independence. Our board of directors has determined that James P. Stapleton is an "independent" director ... The Audit Committee is composed of James P. Stapleton, who is considered an "independent" director ... Summary Compensation Table shows 2007 compensation includes $35,000 warrants.
2010-01-29	For his services as a non-employee director and Chairman of the Audit Committee, James Stapleton was awarded 70,000 warrants to purchase the Company’s common stock at $0.75 per share. These warrants vest immediately.